914
Participants
Start Date
February 29, 2012
Primary Completion Date
April 30, 2019
Study Completion Date
April 30, 2019
No Intervention
No Intervention. Subjects are previously treated with Nulojix (belatacept)
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
New York- Presbyterian/ Weill Cornell Medical Canter, New York
Penn State Milton S. Hershey Medical Center, Hershey
University of Maryland Medical Center, Baltimore
Univ of Virginia HSC, Charlottesville
Carolinas Medical Center, Charlotte
Medical University of South Carolina, Charleston
Emory Healthcare - Emory University Hospital (EUH), Atlanta
Tampa General Hospital, Tampa
The Christ Hospital Cancer Research, Cincinnati
Lutheran Kidney Transplant Center, Fort Wayne
St. Clair Nephrology Research, Detroit
The Iowa Clinic, Des Moines
Medical College of Wisconsin, Milwaukee
University of Minnesota Medical Center, Minneapolis
Northwestern Memorial Hospital, Chicago
University of Illinois Mecial Center, Chicago
University of Chicago Medical Center, Chicago
Barnes-Jewish Hospital, St Louis
Integris Baptist Medical Center, Oklahoma City
UT Southwestern Medical Center, Dallas
University of Colorado School of Medicine, Aurora
Denver Nephrologists, Denver
University of Arizona, Tucson
University of California, Los Angeles, Los Angeles
USC University Hospital, Los Angeles
Cedars-Sinai Med Center, Los Angeles
St. Vincent Medical Center - Los Angeles, Los Angeles
California Institute of Renal Research, San Diego
University of California San Francisco Medical Center, San Francisco
Swedish Medical Center, Seattle
Yale University (Yale New Haven Hospital), New Haven
Maine Medical Center, Portland
Baystate Medical Center, Springfield
Bms Clinical Research Center, Does Not Exist
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
Bristol-Myers Squibb
INDUSTRY